167
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
199
ONSOLIS (fentanyl buccal soluble film): US prescribing information. Somerset (NJ):
Meda Pharmaceuticals Ltd [online]. Verfügbar online über URL:
http://www.onsolis.
com/pdf/onsolis_pi.pdf [aufgerufen am 31.10.2025].
200
Osenbach RK, Harvey S. Neuraxial infusion in patients with chronic intractable cancer
and noncancer pain. Current Pain and Headache Reports 2001; 5: 241-249.
201
Parlow JL, Milne B, Tod DA, Stewart GI, Griffiths JM, Dudgeon DJ. Self-administered
nitrous oxide for the management of incident pain in terminally ill patients: a blinded
case series. Palliative Medicine 2005; 19(1): 3-8.
202
Patt RB, Ellsion NM. Breakthrough pain in cancer patients: characteristics, prevalence
and treatment. Oncology (Huntington) 1998; 12: 1035-1052.
203
Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, Berris R, Busch MA, Nordbrook
E, Loseth DB, Portenoy RK. Long-term safety of oral transmucosal fentanyl citrate for
breakthrough cancer pain. J Pain Symptom Manage. 2001; 22(1): 575-583.
204
Pease N, Taylor H, Major H. Driving advice for palliative care patients taking strong
opioid medication. Palliative Medicine 2004; 18: 663-665.
205
Petzke F, Radbruch L, Zech D, Loick G, Grond S. Temporal presentation of chronic cancer
pain: transitory pains on admission to a multidisciplinary pain clinic. Journal of Pain and
Symptom Management 1999; 17: 391-401.
206
Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. Preva-
lence and characteristics of breakthrough pain in opioid-treated patients with chronic
noncancer pain. Journal of Pain 2006; 7(8): 583-591.
207
Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-
dwelling patients with cancer pain and noncancer pain, part 1: prevalence and charac-
teristics. J Opioid Manag 2010; 6(2): 97-108.
208
Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-
dwelling patients with cancer pain and noncancer pain, part 2: impact on function,
mood, and quality of life. J Opioid Manag 2010; 6(2): 109-116.
209
Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study
Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of
Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain
2010; 151(3): 617-624.
210
Portenoy RK, Forbes K, Lussier D, Hanks G. Difficult pain problems: an integrated ap-
proach. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford Textbook of Palliative
Medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 438-458.
211
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics.
Pain 1990; 41(3): 273-281.
212
Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of break-
through pain in opioid-treated patients with chronic low back pain: a randomized,
placebo-controlled study. Curr Med Res Opin 2007; 23(1): 223-233.
213
Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in
patients with cancer pain. Pain 1999; 81(1-2): 129-134.
Literaturverzeichnis